
U.S. health officials have approved a Gen-Probe Inc. test that can diagnose HIV sooner than other tests currently on the market, the Food and Drug Administration said on Thursday.
The test, called the Aptima HIV-1 RNA Qualitative Assay, helps detect genetic material to diagnose the HIV-1 virus before antibodies appear, the FDA said. It can also help confirm presence of the virus if antibodies are found.
Shares of the San Diego, Calif.–based company closed up 10 cents at $47.72 on Nasdaq after the approval.
The FDA said the Aptima test is as sensitive as other kinds of tests that measure the amount of virus in patients with established HIV infections.
On Wednesday, the FDA approved Gen-Probe's Procleix Ultrio test to screen donated blood, plasma, organs, and tissue for HIV-1 and hepatitis C virus. Ultrio was also cleared to detect the hepatitis B virus. (Reuters)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
Comments that do not concern specific articles in The Advocate or on Advocate.com will not be posted or published. See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.